Compugen to Participate in Stifel 2025 Healthcare Conference
Compugen (Nasdaq: CGEN) announced management will participate in a fireside chat at the Stifel 2025 Healthcare Conference in New York City on Tuesday, November 11, 2025 from 3:20–3:50 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Compugen (Nasdaq: CGEN) announced management will participate in a fireside chat at the Stifel 2025 Healthcare Conference in New York City on Tuesday, November 11, 2025 from 3:20–3:50 PM ET.
A live webcast will be available on the company's Investor Relations website at www.cgen.com, with a replay posted after the event.
Details
News Market Reaction – CGEN
On Nov 4, the day this news came out, CGEN closed 6.94% below the previous close.
Data tracked by StockTitan Argus for the Nov 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON,
A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development, is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in
Company Contact:
Yvonne Naughton, Ph.D.
Vice President, Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-stifel-2025-healthcare-conference-302603899.html
SOURCE Compugen Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.